CVIA Journal

Cardiovascular Innovations and Applications

28th Great Wall International Congress of Cardiology (GW-ICC), 2017, News: China PERT Consortium Launched; Chairman, Professor Nie Shaoping

28th GW-ICC, Beijing, China, October 2017

October 14th 2017; more than 40 researchers from China and the USA gathered at the Eleventh Five-Continents International Cardiovascular Disease Conference in Beijing, China, to mark the initiation of China's Pulmonary Embolism Treatment Consortium (PERT Consortium), marking the start of a new multi-disciplinary treatment model for acute pulmonary embolism.

Professor Kenneth Rosenfield, founder of the PERT Consortium of the United States, Professor Victor F. Tapson, Chairman of the Consortium, and Dean Wei Yongxiang, Beijing Anzhen Hospital affiliated to Capital Medical University, spoke at the launch ceremony. Professor Nie Shaoping (editorial board member, Cardiovascular Innovations and Applications (CVIA)), chairman of the China PERT Consortium, introduced the aims, scope and organization of the China PERT Consortium. Professor Thach Nguyen (editorial board member, CVIA), Cardiovascular Clinic of University of Davenport, Merrillville, USA, pulmonary vascular intensive medical experts from Cedar Mount Sinai Medical Center, USA, Doctor Tao Ling from Xijing Hospital, Doctor Luo Jianfang from Guangdong Provincial People's Hospital, and other experts attended the ceremony.

China PERT Consortium is the first PERT Consortium in Asia, and is an official member of the International PERT Consortium.

abstract41_Figure1

China PERT Consortium Launch Meeting

abstract41_Figure2

Professor Kenneth Rosenfield, Founder of the US PERT Consortium, attended the launch meeting

abstract41_Figure3

Professor Victor F. Tapson, Chairman of the US PERT Consortium

abstract41_Figure4

Professor Dean Wei Yongxiang

Pulmonary embolism is the third major cause of cardiovascular death worldwide. The diagnosis rate of pulmonary embolism is low. Autopsy data of dead patients in international general hospitals show that the positive rate of pulmonary embolism is as high as 13%. Recent international studies have shown that one in every six syncope patient also suffers pulmonary embolism. The mortality of pulmonary embolism at early stage is extremely high. Autopsy studies in the United States show that about 60% of inpatients with unexplained death had pulmonary embolism as the cause of death. Clinical studies have shown that mortality rate of pulmonary embolism within one hour of onset is 10%, and mortality of untreated pulmonary embolism can be as high as 30%, while early diagnosis and effective treatment can avoid 80% of patient deaths.

To improve the treatment efficacy of pulmonary embolism, Professor Kenneth Rosenfield advocated and founded the Pulmonary Embolism Response Team consortium in 2015, aimed at guiding the building and development of PERT teams to improve the diagnosis and treatment of severe pulmonary embolism. At present, more than 50 medical centers in the United States and medical centers from Europe, Africa and elsewhere have joined the Consortium.

abstract41_Figure5

Professor Nie Shaoping, chairman of China consortium of Pulmonary Embolism Response Team

It is estimated that there are more than 300,000 pulmonary embolism inpatients in China annually, while the number of undiagnosed patients is undocumented. Pulmonary embolism is frequently mistaken for other diseases by clinicians, and as a result, the majority of patients do not receive timely diagnosis and effective treatment. Beijing Anzhen Hospital Affiliated to Capital Medical University adheres to the hospital policy of "strong specialty with comprehensive care" in the treatment of cardiopulmonary vascular disease and acute severe patients, combining emergency critical care with the departments of respiratory, cardiac surgery, vascular, cardiology, ultrasonography, and hematology to establish the first international standards multi-disciplinary team of pulmonary embolism treatment in Asia. The team has set up multiple working groups including flow group, clinical group, technical group, research group and contact group, to improve the relevant treatment process, and create a highly efficient and convenient information platform for "a rapid response, joint action, right decision-making" mode of operation, and successful treatment of multiple critically ill patients with pulmonary embolism.

Objectives of China consortium of PERT

At the founding ceremony, Professor Nie Shaoping, Chairman of the China consortium, introduced the working pattern of Anzhen PERT and the next step objectives of China PERT consortium:

  • To promote the concept of team treatment in pulmonary embolism, building a platform for academic, clinical and technical knowledge exchange
  • To introduce new technology of pulmonary embolism treatment, training of a complex treatment team
  • To establish more PERT teams in China, improving the standardized treatment process
  • To carry out relevant clinical research, accumulating Chinese clinical data
  • To strengthen international exchanges and cooperation, especially with advanced PERT Team and PERT consortium in the United States
  • To carry out research and development of medical device for pulmonary embolism treatment, promoting the transformation of innovative and domestic devices for clinical usage.

CVIA Editorial Board members, Dr Nie Shaoping and Dr. Gao Chuanyu are members of the first China PERT consortium.

Speakers

abstract41_Figure6

Kenneth Rosenfield, MD

Kenneth Rosenfield, MD, Professor, FSCAI, FACC, Former Chairman of the American Consortium of Pulmonary Embolism Response Team (PERT), former Chairman of the American Society of Cardiovascular Angiography and Intervention (SCAI), Director of Department of Vascular Medicine and Intervention, Massachusetts General Hospital, Chairman of the STEMI Quality Improvement Committee.

abstract41_Figure7

Victor F. Tapson, MD

Victor F. Tapson, MD, Professor, Chairman of the American Consortium of Pulmonary Embolism Response Team (PERT), Director of the Women's Association for Lung Disease Clinical Research, Director of the Venous Thrombosis and Pulmonary Vascular Disease Research Project, Deputy director of pulmonary vascular and severe disease, Cedars-Sinai Medical Center.

abstract41_Figure8

Dr. Nie Shaoping, Professor, Chief Physician, MD, PhD supervisor, first batch instructor of coronary heart disease intervention training in Cardiovascular Disease Intervention Training Base of the Ministry of Health, International Director of American Society of Cardiovascular Angiography and Intervention (SCAI), International Member (FESC) of European Society of Cardiology (ESC). Current director of the Beijing Anzhen Hospital Emergency Center.

Cardiovascular Innovations and Applications is indexed in the OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ and Index Copernicus Databases
EX-Lib-90x50 OCLC-90x50 sherpa NISC logo Directory of Open Access Journals index-copernicus logo
CVIA Journal © 2015